NCT02906163 2016-09-19First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care TherapySciClone PharmaceuticalsPhase 1/2 Unknown188 enrolled